At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NUVB Nuvation Bio, Inc.
Closed 07-10 16:00:00 EDT
5.81
-0.30
-4.91%
盘后5.85
+0.04+0.69%
19:58 EDT
High6.12Low5.81Vol6.09M
Open6.10D1 Closing6.11Amplitude5.07%
Mkt Cap2.02BTradable Cap1.48BTotal Shares347.60M
T/O35.99MT/O Rate2.39%Tradable Shares255.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Nuvation Bio is Maintained at Buy by Truist Securities
Dow Jones  ·  07-07
Nuvation Bio is Maintained at Buy by Truist Securities
Nuvation Bio Prices Upsized USD 287.5 Million Convertible Senior Notes After Full Greenshoe Exercise
Reuters  ·  07-07
Nuvation Bio Prices Upsized USD 287.5 Million Convertible Senior Notes After Full Greenshoe Exercise
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
THOMSON REUTERS  ·  07-07
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
Nuvation Bio Plans Offering of $200 Million Convertible Senior Notes Due 2032
Reuters  ·  07-01
Nuvation Bio Plans Offering of $200 Million Convertible Senior Notes Due 2032
Nuvation Bio Faces More Predictable Growth Supported by Ibtrozi Frontline Adoption, Wedbush Says
MT Newswires Live  ·  07-01
Nuvation Bio Faces More Predictable Growth Supported by Ibtrozi Frontline Adoption, Wedbush Says
Nuvation Bio's Taletrectinib Enters UK Regulatory Review
MT Newswires Live  ·  06-29
Nuvation Bio's Taletrectinib Enters UK Regulatory Review
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced Ros1-positive Non-small Cell Lung Cancer Validated in the United Kingdom
THOMSON REUTERS  ·  06-29
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced Ros1-positive Non-small Cell Lung Cancer Validated in the United Kingdom
Nuvation Bio (NUVB) Completes $250 Million Note Offering, Is The Stock Fully Priced?
Simply Wall St.  ·  06-28
Nuvation Bio (NUVB) Completes $250 Million Note Offering, Is The Stock Fully Priced?
Exchange-Traded Funds, Equity Futures Decline Pre-Bell Friday as Investors Shift Focus From Middle East to Technology Stocks
MT Newswires Live  ·  06-26
Exchange-Traded Funds, Equity Futures Decline Pre-Bell Friday as Investors Shift Focus From Middle East to Technology Stocks
Nuvation Bio prices upsized offering of $250M of convertible senior notes
TIPRANKS  ·  06-26
Nuvation Bio prices upsized offering of $250M of convertible senior notes
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 Million of Convertible Senior Notes
THOMSON REUTERS  ·  06-26
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 Million of Convertible Senior Notes
Nuvation Bio Slides on Planned $200 Mln Convertible Offering
Reuters  ·  06-25
Nuvation Bio Slides on Planned $200 Mln Convertible Offering
Nuvation Bio falls -10.1%
TIPRANKS  ·  06-25
Nuvation Bio falls -10.1%
Nuvation Bio Plans USD 200 Million Convertible Senior Notes Offering Due 2032
Reuters  ·  06-25
Nuvation Bio Plans USD 200 Million Convertible Senior Notes Offering Due 2032
Nuvation Bio - to Offer $200 Mln Convertible Senior Notes Due 2032
THOMSON REUTERS  ·  06-25
Nuvation Bio - to Offer $200 Mln Convertible Senior Notes Due 2032
Nuvation Bio - Proceeds to Fund Capped Calls, Repay Senior Loan, and General Corporate Purposes
THOMSON REUTERS  ·  06-25
Nuvation Bio - Proceeds to Fund Capped Calls, Repay Senior Loan, and General Corporate Purposes
Nuvation Bio CFO Philippe Sauvage Disposes of 47,668 Common Shares Worth $286,650.16
Reuters  ·  06-25
Nuvation Bio CFO Philippe Sauvage Disposes of 47,668 Common Shares Worth $286,650.16
Nuvation Bio posts corporate deck spotlighting IBTROZI launch, oncology pipeline programs
Reuters  ·  06-17
Nuvation Bio posts corporate deck spotlighting IBTROZI launch, oncology pipeline programs
Nuvation Bio director Robert Mashal reports purchase of 25,000 shares for $118,250
Reuters  ·  06-12
Nuvation Bio director Robert Mashal reports purchase of 25,000 shares for $118,250
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Teva Pharmaceutical (TEVA) and Nuvation Bio (NUVB)
TIPRANKS  ·  06-10
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Teva Pharmaceutical (TEVA) and Nuvation Bio (NUVB)

Introduction

Company Name.
Nuvation Bio, Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung , M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco .
Issue price:
--